Satu Mustjoki

Dr. Satu Mustjoki is a Professor of Translational Hematology at the Faculty of Medicine, University of Helsinki (UH), Finland. She serves as Director of the Translational Immunology Research Program (2019-2025), Scientific Director of the iCAN Digital Precision Cancer Medicine Flagship (2022-2026), and leads multiple international research consortia including EraPerMed EU and Heal-Art projects.

• Adjunct Professor (2011), Experimental Hematology, UH
• Specialist in Clinical Chemistry (2008), UH
• PhD (2001), UH
• MD (1997), UH

Her research focuses on somatic mutations in hematological malignancies and autoimmune diseases, cancer immunology, and personalized medicine. The work integrates immunogenomics, functional genomics, and clinical translation to identify novel therapy targets and biomarkers.

Recent publications highlight somatic mutation analysis in T cells (chronic GVHD, RA), NK cell interactions with blood cancers, and single-cell approaches to melanoma immunotherapy. Key themes include mutation-driven immune dysregulation and precision targeting of apoptotic pathways in leukemia.

• Helsinki Institute of Life Science (HiLife) Fellow (2017-2025)
• ERC Consolidator grant awardee (2015-2020)
• Biomedicum Helsinki award (2018)
• City of Helsinki Science award (2020)
• Academy of Finland Senior Research Fellowship (2010-2015)

She supervises 9 completed + 9 ongoing post-doctoral researchers, 18 completed + 13 ongoing PhD students, and 22 completed MSc/MD theses. Funding includes major grants from the Erkko Foundation, Leukemia & Lymphoma Society, and Academy of Finland. She participates in European and American hematology scientific committees and leads international clinical studies as principal investigator.